This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leibovitz, E. Articles by Barak, Y. Search for Related Content PubMed PubMed Citation Articles by Leibovitz, E. Articles by Barak, Y. Social Bookmarking                   What's this?

Once-Daily Intramuscular Ceftriaxone in the Outpatient Treatment of Severe Community-Acquired Pneumonia in Children

Department of Pediatrics, Division of Infectious Diseases, New York University Medical Center/Bellevue Hospital, 550 First Avenue, New York, N.Y. 10016

Elvan Tabachnik, MD

Department of Pediatrics, Kaplan Hospital

Orna Fliedel, MD

Department of Pediatrics, Kaplan Hospital

Shoshana Steinberg, MD

Department of Pediatrics, Kaplan Hospital

Avraham Miskin, Ph.D

and Department of Microbiology Laboratories, Kaplan Hospital, Rehovot

Asaria Askenazi, MD

Department of Pediatrics, Kaplan Hospital

Yigal Barak, MD

Department of Pediatrics, Kaplan Hospital

Ceftriaxone, a broad spectrum third-generation cephalosporin with a half-life of six to eight hours, was evaluated prospectively in 147 children with severe community-acquired bacterial pneumonia during the period 11/15/88-5/15/89. Thirty-nine of the children had been successfully treated with various oral antibiotics prior to admission. All the patients were initially hospitalized and started on once a day intramuscular ceftriaxone. Mean duration of ceftriaxone therapy was five days. Pathogens were recovered from blood cultures of 17 (11.6%) patients and included S. pneumoniae (13 patients), H. influenzae (three, all resistant to ampicillin) and S. viridans.¹ All isolates were sensitive to ceftriaxone. An additional patient had L. pneumophila diagnosed by serology. Cure was achieved in 142 (96.6%) patients; improvement was usually observed within 24-48 hours. After 48 hours, 121 (82.2%) children could be discharged and continued the therapy on ambulatory basis. Based on previous experience we estimated that 383 hospitalization days were saved. No serious side effects were observed. Five patients were considered therapeutic failures; two of them developed empyema and one of them required repeated drainage procedures. A third patient experienced a relapse of pneumonia shortly after completion of therapy. The other two remained febrile for more than seven days; their subsequent improvement was unrelated to the antibiotic therapy, suggesting a viral or mycoplasmal syndrome. Our data suggest that once daily intramuscular ceftriaxone can be successfully used for the outpatient treatment of most community-acquired severe bacterial pneumonias in children. In our opinion it represents the treatment of choice for patients who failed treatment with other antimicrobials and are clinically stable enough not to require hospitalization.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H Ashraf, S A Jahan, N H Alam, R Mahmud, S M Kamal, M A Salam, and N Gyr Day-care management of severe and very severe pneumonia, without associated co-morbidities such as severe malnutrition, in an urban health clinic in Dhaka, Bangladesh Arch. Dis. Child., June 1, 2008; 93(6): 490 - 494. [Abstract] [Full Text] [PDF]